Biotechnology

Genetic Engineering Drug Development Genetics Nanotechnology Pharmaceuticals Vaccine Development Gene Therapy Research and Development Synthetic Biology Gene Editing

UCB to Buy Candid Therapeutics for Up to $2.2 Billion

The buyout expands UCB's push into T‑cell engager drugs for autoimmune diseases.

Stories older than 24h

Mayo Clinic AI Flags Pancreatic Cancer on CT Years Before Diagnosis

LEO Pharma to Acquire Replay in $50 Million Gene-Therapy Deal

Former Harvard Scientist Charles Lieber Now Leads China’s State-Backed Brain-Interface Program

AI-Designed E. coli Ribosomes Operate Without Isoleucine

Pfizer Settles With Three Generics to Keep Vyndamax Exclusive Until 2031

Lilly and Profluent Strike AI Gene-Editing Pact Worth Up to $2.25 Billion

Gilead Closes $7.8 Billion Arcellx Deal to Take Full Control of Anito‑cel

Sagimet Prices $175 Million Stock Offering as It Plans U.S. Phase 3 Acne Trial

Lilly to Acquire Ajax Therapeutics in Up to $2.3 Billion Blood Cancer Deal

Injection Eases Breathing in Flat-Faced Dogs in Small Australian Trial

On-Demand Nanobody Probes Sharpen Live Imaging by Lighting Up Only at Targets

Trump Order to Speed Psychedelic Therapies Sends Compass Pathways to 52-Week High

Nanopillared Plastic Film Rips Virus Particles Apart on Contact

Eli Lilly to Buy Kelonia for Up to $7 Billion to Gain In‑Vivo CAR‑T Platform

Roche Starts Placebo-Controlled Phase 3 Trial of Elevidys to Pursue EU Approval

Traws Pharma Raises $10 Million in PIPE With Up to $60 Million Tied to Trial Milestones

Engineered Mini CRISPR Achieves Up to 90% Editing in Human Cells

Senhwa Signs MOU With GEM for Up to NT$500 Million to Speed AI-Driven Cancer R&D

FDA Grants Priority Review to Ifinatamab Deruxtecan for Pretreated Small Cell Lung Cancer